CLAIMS

1. Use of *L. rhamnosus* HN001, AGAL deposit number NM97/09514 dated 18 August 1997, in the manufacture of a composition or medicament for treating or preventing gestational diabetes mellitus (GDM), or one or more GDM-associated risks or one or more sequelae of GDM in an adult female subject, and wherein the fasting mean blood glucose level is lowered in the subject to less than about 4.35 mmol/l.

2. Use of *L. rhamnosus* HN001, AGAL deposit number NM97/09514 dated 18 August 1997, in the manufacture of a composition or medicament for preventing one or more GDM-associated risks or one or more sequelae of GDM in a foetal, neonatal, infant or child subject, wherein the composition or medicament is to be administered to the pregnant mother of the foetal, neonatal, infant or child subject during gestation, and wherein the fasting mean blood glucose level is lowered in the pregnant mother of the foetal, neonatal, infant or child subject to less than about 4.35 mmol/l.

3. The use of claim 1 or 2, wherein the composition or medicament comprises a physiologically acceptable diluent, adjuvant, carrier or excipient.

4. The use of any one of claims 1-3, wherein the composition or medicament comprises or is formulated as
   (1) a pharmaceutical composition comprising a pharmaceutically acceptable diluent, adjuvant, carrier or excipient,
   (2) a maternal formula or a maternal supplement, or
   (3) a supplement, formula, or dietetic product.

5. The use of any one of claims 1-4, wherein the *L. rhamnosus* HN001 is in a reproductively viable form.

6. The use of any one of claims 1-4, wherein the *L. rhamnosus* HN001 is killed, lysed, fractionated or attenuated.

7. The use of any one of claims 1-6, wherein the adult female subject, or the mother of a foetal, neonatal, infant or child subject, has an increased risk of GDM.

8. The use of claim 7, wherein the adult female subject, or the mother of a foetal, neonatal, infant or child subject, has previously suffered GDM, and/or has been previously been pregnant.

9. The use of any one of claims 1-8, wherein
    a. the *L. rhamnosus* HN001, the composition or the medicament is to be administered after the first trimester of pregnancy,
    b. the *L. rhamnosus* HN001, the composition or the medicament is to be administered between 14 – 16 weeks gestation,
    c. the *L. rhamnosus* HN001, the composition or the medicament is to be administered from 14 to 16 weeks gestation until delivery, or
    d. the *L. rhamnosus* HN001, the composition or the medicament is to be administered from 14 to 16 weeks gestation to 6 months post-partum.

10. The use of any one of claims 1-9, wherein
    a. the treatment is prophylactic treatment,
    b. the treatment is prophylactic treatment of an adult female subject having an expected or established increased risk of GDM,
    c. the treatment is prophylactic treatment of an adult female subject attempting to become or recently pregnant,
    d. the treatment is prophylactic treatment of a foetal subject by administration of the composition or medicament to the foetal subject's mother, or
    e. the treatment is prophylactic treatment of a neonatal, infant or child subject by administration of the composition or medicament to the subject's mother.

11 The use of any one of claims 1-10, wherein
    a. the adult female subject is pregnant,
    b. the adult female subject, or the mother, is 35 years or older,
    c. the adult female subject, or the mother, is pregnant and is 35 years or older,
    d. the adult female subject, or the mother, is pregnant and has a history of GDM,
    e. the adult female subject, or the mother, is pregnant, is 35 years or older, and has a history of GDM,
    f. the subject is a foetal subject and the *L. rhamnosus* HN001, or the composition or medicament is to be administered to the subject's mother, or

g. the subject is a neonatal, infant, or child subject, and the *L. rhamnosus* HN001, or the composition or medicament is to be administered to the subject's mother.

12. The use of any one of claims 1-11, wherein the composition or medicament is formulated for simultaneous or sequential administration with a prebiotic.

13. The use of claim 12, wherein the prebiotic comprises fructooligosaccharides, galactooligosaccharides, or human milk oligosaccharides, or a combination thereof.

14. The use of any one of claims 1-13, wherein the adult female subject, or the mother of the foetal, neonatal, infant or child subject, has a BMI of less than 30kg/m^2.